Stanley Bergman - Henry Schein Ex CEO
| HS2 Stock | EUR 66.06 1.76 2.60% |
Insider
Stanley Bergman is Ex CEO of Henry Schein
| Age | 73 |
| Phone | 631 843 5500 |
| Web | https://www.henryschein.com |
Stanley Bergman Latest Insider Activity
Tracking and analyzing the buying and selling activities of Stanley Bergman against Henry Schein stock is an integral part of due diligence when investing in Henry Schein. Stanley Bergman insider activity provides valuable insight into whether Henry Schein is net buyers or sellers over its current business cycle. Note, Henry Schein insiders must abide by specific rules, including filing SEC forms every time they buy or sell Henry Schein'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Stanley Bergman over three months ago Disposition of 634 shares by Stanley Bergman of Henry Schein subject to Rule 16b-3 | ||
Stanley Bergman over three months ago Disposition of 14080 shares by Stanley Bergman of Henry Schein subject to Rule 16b-3 | ||
Stanley Bergman over six months ago Disposition of 475 shares by Stanley Bergman of Henry Schein subject to Rule 16b-3 |
Henry Schein Management Efficiency
The company has return on total asset (ROA) of 0.0642 % which means that it generated a profit of $0.0642 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1211 %, meaning that it generated $0.1211 on every $100 dollars invested by stockholders. Henry Schein's management efficiency ratios could be used to measure how well Henry Schein manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Man Cho | Shanghai Pharmaceuticals Holdin | 62 | |
| Liang Hong | Shanghai Pharmaceuticals Holdin | 43 | |
| PharmD Mauch | AmerisourceBergen | 56 | |
| Haoliang Gu | Shanghai Pharmaceuticals Holdin | 57 | |
| Wanyong Lian | Sinopharm Group Co | 52 | |
| Yong Liu | Sinopharm Group Co | 54 | |
| Tao Zhong | Shanghai Pharmaceuticals Holdin | 51 | |
| Jianyi Mao | Shanghai Pharmaceuticals Holdin | 50 | |
| Min Zuo | Shanghai Pharmaceuticals Holdin | 57 | |
| Kathy Gaddes | AmerisourceBergen | 60 | |
| Ying Ke | Shanghai Pharmaceuticals Holdin | N/A | |
| Gina Clark | AmerisourceBergen | 66 | |
| Xiuchang Jiang | Sinopharm Group Co | 59 | |
| Yaohua Zhang | Shanghai Pharmaceuticals Holdin | 45 | |
| John Wright | Patterson Companies | N/A | |
| Shunjiang Yu | Shanghai Pharmaceuticals Holdin | N/A | |
| Paul Guggenheim | Patterson Companies | 63 | |
| James Cleary | AmerisourceBergen | 60 | |
| Philip Terpolilli | Prestige Consumer Healthcare | N/A | |
| Patricia English | Cardinal Health | 43 | |
| Maisong Cai | Sinopharm Group Co | 53 | |
Management Performance
| Return On Equity | 0.12 | |||
| Return On Asset | 0.0642 |
Henry Schein Leadership Team
Elected by the shareholders, the Henry Schein's board of directors comprises two types of representatives: Henry Schein inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Henry. The board's role is to monitor Henry Schein's management team and ensure that shareholders' interests are well served. Henry Schein's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Henry Schein's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Ettinger, Ex COO | ||
| Walter Siegel, VP Officer | ||
| Graham Stanley, VP Officer | ||
| Stanley Bergman, Ex CEO | ||
| Steven Paladino, Ex Director | ||
| Ronald South, VP CFO | ||
| Mark Mlotek, Chief VP | ||
| Olga Timoshkina, Chief Fin | ||
| Christopher Pendergast, VP CTO | ||
| James Breslawski, Ex Pres |
Henry Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Henry Schein a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.12 | |||
| Return On Asset | 0.0642 | |||
| Profit Margin | 0.04 % | |||
| Operating Margin | 0.07 % | |||
| Current Valuation | 11.9 B | |||
| Shares Outstanding | 131.28 M | |||
| Shares Owned By Insiders | 1.01 % | |||
| Shares Owned By Institutions | 98.99 % | |||
| Price To Earning | 16.81 X | |||
| Price To Book | 3.09 X |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Henry Stock
When determining whether Henry Schein offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Henry Schein's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Henry Schein Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Henry Schein Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Henry Schein. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Henry Stock please use our How to Invest in Henry Schein guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.